US regulator tightens drug approval norms

Companies asked to give data for three batches instead of one; move may lead to significant rise in development cost of genericsPharmaceutical companies operating in the US might be in for a......

Indian drug makers face heat of US regulator's crackdown

Data also show that several other leading domestic pharma companies have recalled their products from the US Frequent drug recalls, warning letters and import alerts from the US in the recent past......

Wait for Indian generic launches gets longer

Indian generic drug makers, such as Ranbaxy, Lupin, Dr Reddy's and Aurobindo, which often opt to challenge patents in the US, might have to wait longer to launch their generic versions there. For......

Cipla rejigs China investment to focus on niche verticals

Drug maker Cipla Ltd is rejigging its China business. The pharma company recently exited a significant part of its investment in its Chinese partner Desano Holdings, while ploughing back a part of......